4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is a Healthcare company (Biotechnology) with a market capitalization of $596M. The Maz Rating grades it against the other companies in its sector.
4D Molecular Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.79, 4D Molecular Therapeutics, Inc. trades at 6.2x sales and 2.3x book value. Over the last twelve months it generated about $96M of revenue and a net loss of $154M. It runs a gross margin of 91.5%, an operating margin of -226.0% and a net margin of -208.6%. It shows return on equity of -47.1%, return on invested capital of -56.9% and a free cash flow yield of -28.1%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 6.15. Over the past 52 weeks the share price ranged from $6.96 to $16.93, with a beta of 2.91.
4D Molecular Therapeutics, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 11 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.